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Multi-protein complexWe have developed an approach for directly isolating an intact multi-protein chromatin remodeling com-
plex from mammalian cell extracts using synthetic peptide afﬁnity reagent 4. FOG1(1–15), a short pep-
tide sequence known to target subunits of the nucleosome remodeling and deacetylase (NuRD) complex,
was joined via a 35-atom hydrophilic linker to the StreptagII peptide. Loading this peptide onto Strept-
actin beads enabled capture of the intact NuRD complex from MEL cell nuclear extract. Gentle biotin elu-
tion yielded the desired intact complex free of signiﬁcant contaminants and in a form that was
catalytically competent in a nucleosome remodeling assay. The efﬁciency of 4 in isolating the NuRD com-
plex was comparable to other reported methods utilising recombinantly produced GST–FOG1(1–45).
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
To analyse the structure and function of multi-protein com-
plexes they must ﬁrst be obtained in their native form and in suf-
ﬁcient quantities for biophysical and biochemical analysis.1–3
Expression of individual subunits and in vitro reconstitution of
the protein complex is often undertaken but can be difﬁcult for
multi-protein complexes with many subunits.4,5 An alternative
approach is to isolate the endogenous complex directly from cell
extracts using protein-derived afﬁnity baits.6,7 Although this typi-
cally yields smaller quantities of protein, sufﬁcient material can
be obtained for conducting preliminary analysis on the composi-
tion, structure and functional activity of the complex.8–10
We are interested in using synthetic molecules to isolate intact
proteins and protein complexes from cell extracts. In a typical
approach, peptides and small molecules are immobilized onto bio-
compatible solid supports through covalent attachment or using
the biotin–streptavidin interaction and used in pulldown-LC–MS/
MS experiments to identify their cellular targets.11,12 In such sys-
tems, elution of captured proteins requires harsh, denaturing con-
ditions and the structural and functional information containedwithin the captured protein complex is lost. We sought to develop
an approach whereby short peptide or small molecule baits could
be combined with afﬁnity tags that enable gentle elution of the
captured proteins. In developing such an approach we focused on
isolating the multi-subunit nucleosome remodeling and deacetyl-
ase (NuRD) complex.
The NuRD complex consists of at least 10 protein components:
RBBP7, RBBP4, HDAC1, HDAC2, MTA1, MTA2, GATAD2A, GATAD2B,
MBD2 or 3 and CHD413 (Fig. 1A). The NuRD complex is unique as a
chromatin remodeler because it combines two catalytic activities—
ATP-dependent chromatin remodeling and lysine deacetylation.
Through these two activities it is able to convert chromatin
between open, poised and closed states14,15 to regulate gene
expression. In previous work, the NuRD complex was puriﬁed in
a single step from murine erythroleukemia (MEL) cell nuclear
extract by afﬁnity chromatography using GST-fusions of the ﬁrst
45 residues of the transcriptional co-regulator Friend of GATA 1
(GST–FOG1(1–45))16 and later using the ﬁrst 12 residues of the
FOG2 (GST–FOG2(1–12)).17 Recently a crystal structure of the
NuRD component RBBP4 bound to FOG1(1–15) was reported18
and this, along with additional biochemical experiments, revealed
an Arg-Arg-Lys-Gln motif to be central to the FOG1–RBBP4 interac-
tion (Fig. 1B). We decided to develop synthetic molecules based on
this 15-residue domain from FOG1 as baits to capture the NuRD
complex from MEL cell extracts.
Figure 1. (A) Schematic of the nucleosome remodeling and deacetylase (NuRD) complex showing the well established subunits within the complex. (B) Crystal structure of
FOG1(1–15) bound to RBBP4 (pdb 2XU7). The key RRKQ motif is shown.
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We ﬁrst sought to conﬁrm that FOG1(1–15) could indeed
recruit the NuRD complex from MEL nuclear extract. We obtained
FOG1(1–15) biotinylated at the C-terminus via the side chain of an
additional lysine residue (bFOG1(1–15), 1). In three parallel exper-
iments, peptide 1 was loaded onto streptavidin beads and then
incubated with a nuclear extract prepared from cultured MEL cells.
Each set of beads was then washed with a different salt concentra-
tion, then the bound proteins were eluted by heat denaturation
and the eluates for each experiment were analysed by SDS PAGE.
Figure 2 shows the presence of many protein bands in the eluate
from beads washed with 150 mM NaCl. However, when the beads
were washed with higher salt concentrations (300 mM NaCl and
500 mM NaCl), fewer protein bands were observed in the eluates
by SDS–PAGE. To conﬁrm the presence of NuRD proteins, the gel
lane corresponding to the eluate of beads washed with 300 mM
NaCl was cut it into 10 pieces, each was individually digested with
trypsin and the extracted peptides were analysed by LC–MS/MS.
The NuRD components RBBP4, RBBP7, HDAC1, HDAC2, MTA1,
MTA2, GATAD2A, GATAD2B, MBD3, MBD2 and CHD4 were allFigure 2. SDS PAGE analysis of eluates from protein pulldowns from MEL cell
nuclear extract using 1 (bFOG1(1–15)) and different concentrations of salt during
bead washes. Gel stained with Sypro-Ruby.identiﬁed with 1–50 signiﬁcant peptides and Mascot scores >500
(see Supporting information), demonstrating that 1 can recruit
the entire NuRD complex. The data also show that a signiﬁcant
amount of non-speciﬁc binding takes place under these conditions.
To facilitate gentle elution of the captured NuRD complex we
next chose to investigate FOG1(1–15) joined to the StreptagII pep-
tide afﬁnity tag. This peptide tag can be loaded onto commercially
available Streptactin beads and gently eluted using biotin or
desthiobiotin.19 A relative comparison of peptide tags for afﬁnity
puriﬁcation indicated that the StreptagII–Streptactin system gives
the best compromise between highly speciﬁc capture (e.g., relative
to 6xHis-NiNTA), and cost of the afﬁnity resin (e.g., relative to FLAG
and HA antibody resins).20 Therefore we decided to pursue this
approach.
Initially we synthesised FOG1(1–15) with the eight-residue
StreptagII peptide at the C-terminus (2, Fig. 3), loaded it onto
Streptactin beads and attempted to pulldown the NuRD complex
from MEL cell nuclear extracts. We attempted to elute 2, along
with any captured proteins, by three treatments with 10 mM bio-
tin. However, no NuRD subunits were observed by SDS–PAGE in
the elutions (Fig. 4A). We reasoned that upon binding to the Strept-
actin beads, peptide 2 might position the NuRD recruiting FOG1
domain in an awkward orientation that renders it unable to bind
to RBBP4 or other NuRD components. We therefore prepared a sec-
ond peptide in which the FOG1 domain and StreptagII peptide
were separated by an aminohexanoic acid linker (3, Fig. 3) and
repeated the pulldown from MEL cell nuclear extract (Fig. 4A).
Once again, no NuRD proteins were observed by SDS–PAGE. Next,
we decided to introduce a much longer linker between the Strept-
agII and FOG1(1–15). We also decided to incorporate ﬂuorescein
into the molecule so we could visually monitor peptide attachment
to, and elution from, the beads.
The new peptide (4) was assembled entirely on solid phase
according to Figure 3. After preparing the 8-residue StreptagII pep-
tide, the bifunctional amine 4,7,10-trioxa-1,13-tridecanediamine
was incorporated at the N-terminus via a urea linkage. Introduc-
tion of this linker was conducted at 20 C to minimise hydantoin
formation21,22 which could prematurely cap the growing peptide
chain. A lysine residue modiﬁed at its side chain Ne with carboxy-
ﬂuorescein was then incorporated, followed by attachment of a
second molecule of 4,7,10-trioxa-1,13-tridecanediamine through
a urea linkage. The FOG1 peptide was then assembled to produce
peptide 4which had a 35-atom spacer between the StreptagII pep-
tide and FOG1(1–15). This synthetic strategy gave the desired pep-
tide in 13% puriﬁed yield and could quickly provide hundreds of
milligrams that could conveniently be stored as a solid or in frozen
aliquots.
Peptide 4 was then immobilized on Streptactin beads and
incubated with MEL cell nuclear extract. The beads were washed
in 500 mM NaCl and elution with 10 mM biotin was performed.
Figure 3. Synthesis of FOG1-StreptagII peptides 2–7. (a) SPPS; (b) (i) 20% piperidine/DMF, (ii) CDI, DMF, 20 C, (iii) 4,7,10-trioxa-1,13-tridecanediamine, 20 C; (c) (i)
Fmoc-Lys(Mtt)-OH, HBTU, DIPEA, (ii) 5% TFA/DCM, (iii) 5(6)-carboxyﬂuorescein, HBTU, DIPEA; (d) (i) 20% piperidine/DMF, (ii) CDI, DMF, 20 C, (iii) 4,7,10-trioxa-1,
13-tridecanediamine, 20 C, (iv) SPPS. (e) TFA/TIPS/H2O/EDT/thioanisole (90/2.5/2.5/2.5/2.5).
Figure 4. SDS PAGE analysis of pulldowns from MEL cell nuclear extract. (A) Using FOG1(1–15)-StreptagII peptides (2–4). (B) Using peptides 4–7. (C) Comparison of NuRD
capture with 4 using preloading or direct ‘one-pot’ incubation strategies. PC = pyruvate carboxylase. (D) Comparison of pulldowns using GST–FOG1(1–45) (left) and 4 (right).
(E) Dot blot analysis of eluted proteins captured using peptide 4 or buffer. (F) Chromatin remodeling activity of eluted NuRD compared to the known remodeler CHD1.
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were now observed by SDS PAGE in the eluted fractions (Fig. 4A).
In contrast to 1, peptide 4 was able to strongly retain NuRD pro-
teins even in high salt conditions suggesting that the long linker
may allow for optimal binding or increased avidity.
We next sought to determine whether the entire FOG1(1–15)
motif was required to effectively pull-down the NuRD complex
from MEL nuclear extracts. Analysis of the FOG1–RBBP4 crystal
structure and previous mutagenesis data indicated that the RRKQ
motif was the critical determinant of binding. We therefore
expected that shorter peptides retaining this motif might still be
able to pull down the complex. Three additional peptides (5–7)
were prepared (Fig. 3), each with three residues successively
removed from the C-terminus of the FOG1(1–15) domain.
Figure 4B shows pulldowns conducted with each of these pep-
tides; neither 6 nor 7 were able to pull down the NuRD complex.
Peptide 5 maintained some ability to pull-down NuRD, however,
it was far less effective than the entire FOG1(1–15) sequence in
4. These results suggest that truncating the FOG1(1–15) below
15 residues severely impedes its ability to bind to the endogenous
NuRD complex. It is not clear why this is the case given that the
RRKQ motif is preserved. Additional interactions by the three C-
terminal residues may be important.
Our experiments thus far had utilised 4 that had been loaded
onto Streptactin beads prior to incubation with MEL cell extract.
Biotinylated small molecule afﬁnity baits are often directly incu-
bated with cells or cell extracts and then captured, along with their
bound proteins, by incubation with streptavidin beads.23,24 We
decided to test the efﬁciency of this latter approach for isolating
the NuRD complex using 4. Figure 4C demonstrates that the yield
of NuRD is much higher using our initial approach of preloading
4 onto the Streptactin beads prior to incubation with the cell
extract. The yield of NuRD complex was much less when 4 was
incubated directly with MEL cell extract and then captured using
Streptactin beads. We observed an additional band by SDS–PAGE
when using the direct incubation approach. LC–MS/MS determined
that this protein was pyruvate carboxylase, an endogenously bio-
tinylated protein able to bind with high afﬁnity to the Streptactin
beads.
We expressed GST–FOG1(1–45), which has previously been
used to isolate the NuRD complex from MEL cells16, and assessed
its ability to pull down NuRD compared to peptide 4. Figure 4D
shows that the band pattern observed from pulldowns with GST–
FOG1(1–45) was exactly the same as with peptide 4 and demon-
strates that peptide reagent 4 performed as well as GST–FOG1(1–
45) in pulling down the NuRD complex from MEL cell extract.
Avoiding the use of GST is beneﬁcial because of its tendency to
dimerise which could complicate downstream biochemical and
structural investigations. Although GST can be cleaved, it would
be better not to add a protease to such a large complex with signif-
icant regions of predicted disorder that might also be susceptible to
proteolysis.
To conﬁrm that the observed bands were indeed NuRD proteins,
the gel bands were excised, digested and analysed by LC–MS/MS.
In all cases, the expected NuRD proteins were identiﬁed as the
top protein hits (see Supporting information). A dot blot analysis
was also conducted on the eluent from peptide 4 using antibodies
against CHD4, HDAC1, HDAC2, MTA1 and RBBP7 (Fig. 4E). A posi-
tive result was obtained for all of the antibodies providing further
evidence that the proteins observed by SDS–PAGE were indeed
NuRD proteins.
Finally, we tested the ability of the NuRD complex puriﬁed
using peptide 4 to reposition nucleosomes in vitro. CHD1, a known
chromatin remodeler25 was used as a positive control and could, in
the presence of ATP, reposition a nucleosome in which the recom-
binant histone octamer is bound to a 194-bp DNA fragment. Whenthe puriﬁed NuRD complex was incubated with the nucleosome in
the presence of ATP, the appearance of a new band indicated that
the histone octamer was repositioned on the DNA template
(Fig. 4F) in a similar manner to CHD1. This observation indicated
that the puriﬁed NuRD complex was catalytically active.
3. Conclusion
In summary, we have developed synthetic molecules capable of
isolating the intact and catalytically active NuRD complex from
mammalian cells. By joining FOG1(1–15) to the StreptagII peptide
via a long, 35-atom linker we generated peptide 4 that was as efﬁ-
cient at isolating the NuRD complex as GST–FOG1(1–45) and
avoided potential problems such as GST dimerisation or off-target
cleavage during proteolytic GST removal. The afﬁnity reagents
described herein can be prepared in useful quantities, incorporate
additional features such as ﬂuorescent tags, can be stored for long
periods at low temperature, and can be applied to any speciﬁc pep-
tide sequence or small molecule that is known to target a speciﬁc
protein or protein complex.
4. Experimental
4.1. General
bFOG1(1–15) (1, MSRRKQSNPRQIKRSK(biotin)) was purchased
from ChinaPeptides. Fmoc-amino acids and resins were obtained
from Merck (Melbourne, Australia). Dimethylformamide (DMF),
triﬂuoroacetic acid (TFA), N,N-diisopropylethylamine (DIPEA) and
piperidine were peptide grade and from Auspep (Parkville, Austra-
lia). O-Benzotriazole-N,N,N0,N0-tetramethyluronium hexaﬂuoro-
phosphate (HBTU) was from IRIS Biotech (Germany). All other
chemicals were purchased from Sigma Aldrich. Cell culture media,
additives, resins, gels and enzymes were purchased from Life tech-
nologies. Preparative rpHPLC was performed on a Phenomenex C18
column (100 Å, 250  20 mm). Analytical rpHPLC was performed
on a Phenomenex Luna 5 lm C18 column. Peptides were puriﬁed
using gradient mixtures of water/0.1% TFA and 90% acetonitrile/
0.1% TFA. Purity was checked under different gradients to conﬁrm
single products. Molecular weights were determined using a Voy-
ager DE-STR MALDI mass spectrometer.
4.2. Peptide synthesis
Peptides were assembled by manual solid phase peptide syn-
thesis (SPPS) in Teﬂon syringes ﬁtted with a frit (Torviq). Peptides
were synthesised on 0.1 mmol scale on Rink Amide MBHA resin
(Novabiochem, 0.59 mmol/g).
4.2.1. Fmoc deprotections
The peptide resin was treated twice with 20% piperidine in DMF
for 3 min. The resin was then washed with DMF ﬁve times.
4.2.2. Coupling
0.5 mmol of Fmoc-amino acid was dissolved in 1 mL of 0.5 M
HBTU. 87 lL of DIPEA (0.5 mmol) was added and the mixture vor-
texed for 20 s and then added to the peptide resin. Couplings pro-
ceeded for 15 min at room temperature. After coupling the liquid
was ejected from the syringe and capping solution added
immediately.
4.2.3. Capping
55 lL acetic anhydride (0.5 mmol) was dissolved in 1 mL DMF
and 87 lL of DIPEA (0.5 mmol) was added. The mixture was mixed
vigorously for 20 s and then added to the peptide resin. Capping
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was ejected and the resin washed twice with DMF.
4.2.4. Cleavage
Peptide resins were washed with DMF and then DCM and
transferred to a scintillation vial with a stirrer bar. The resin was
then treated with 90% TFA, 2.5% triisopropylsilane, 2.5% H2O,
2.5% ethanedithiol, and 2.5% thioanisole for 2 h at room tempera-
ture. Peptides were subsequently isolated by evaporation of the
cleavage mixture and ether precipitation.
4.2.5. HPLC
Peptides were puriﬁed on GBC HPLC system using a Phenome-
nex Jupiter C18 column (10 lm, 300 Å, 250 mm  15 mm) linear
gradient of 0–70% B over 35 min at 3 mL/min. Fractions were ana-
lysed by MALDI-MS, analysed by rpHPLC to ensure >95% purity and
lyophilized.
4.3. Strep-tagged peptides (4–7)
The StreptagII peptide was assembled using standard proce-
dures. Then the N-terminal amino group was activated with a
pre-cooled (20 C) solution of carbonyldiimidazole (1 mmol,
10 equiv) in 2 mL DMF for 1 h at 20 C by placing the reaction
vessel in a freezer. Following washing with pre-cooled (20 C)
solution of DMF (3  5 mL), a pre-cooled (20 C) 1:1 mixture
of DMF and 4,7,10-trioxa-1,13-tridecanediamine (4 mL) was incu-
bated with the resin for 1 h at 20 C. Fmoc-Lys(Mtt)-OH was
subsequently coupled to the N-terminus and the Mtt group was
removed from the side chain epsilon amino group by 5  3 min
treatments with 3% TFA in DCM with 3% TIPS. 5(6)-carboxyﬂuo-
rescein was coupled on to the lysine side chain using HBTU/
DIPEA activation and reacting with the resin overnight. Then
the Fmoc group was removed and a second 4,7,10-trioxa-1,13-
tridecanediamine linker was installed using CDI activation
protocol above. Finally, the FOG1 peptides were assembled using
standard SPPS methodology.
4.4. Cell culture
Murine erythroleukemia (MEL) cells were cultured in DMEM
medium (+glucose, +glutamine, +pyruvate) supplemented with 5%
FBS and 1% penicillin/streptomycin. 10–20 mL seed cultures were
maintained and for large scale grow-ups a 1 mL seed culture was
added to 250 mL freshmedium and grown at 37 C, 5% CO2 to a den-
sity of 1  106 cells/mL (viability >85%). Cells were harvested by
centrifugation at 2000 rpm for 5 min to yield 1 g (wet weight)
cells/L culture. Cells were washed twice with PBS, then swollen in
hypotonic solution (10 mM HEPES, 1.5 mM MgCl2, 10 mM KCl, pH
7.9) for 20 min and frozen in liquid nitrogen and stored at 80 C
until use.
4.5. Nuclear extract preparation
Frozen, swollen cells were thawed at 37 C for 10 min. IGEPAL
was added to a ﬁnal concentration of 0.6% (v/v) and cells were
incubated for 10 min to lyse the cell membrane. The mixture was
centrifuged for 5 min at 2000 rpm to pellet nuclei and the cytoplas-
mic supernatant was discarded. The pellet was gently washed once
with hypotonic solution (10 mM HEPES, 1.5 mM MgCl2, 10 mM
KCl, pH 7.9, 0.6% IGEPAL) and centrifuged again at 2000 rpm. Next,
buffer A (50 mM Tris, 150 mM NaCl, 1% Triton X-100, 1 mM DTT,
Complete protease inhibitors, pH 7.4) was added to the pellet
(3 mL/g cells) and the mixture was sonicated on ice (step-tip,
10  1 s bursts with 10 s recovery, three times total) to give a
milky white solution. The mixture was centrifuged at 13000 rpmfor 10 min at 4 C. The clear nuclear extract was then used
immediately.
4.6. Afﬁnity resin preparation
Streptavidin or Streptactin beads 50 lL (300 nmol/mL, 15 nmol)
were washed three times with water, and then three times with
buffer A (50 mM Tris, 150 mM NaCl, 1% Triton X-100, 1 mM DTT,
Complete protease inhibitors, pH 7.4). Peptides (50 nmol, dissolved
in 50 lL buffer A) were added to the beads and incubated at 4 C
for at least 2 h. The beads were then washed three times with buf-
fer A and used immediately.
4.7. Pulldown
The nuclear extract was incubated with the peptide afﬁnity
resin overnight at 4 C. The next morning the beads were separated
from the nuclear extract and washed three times with high salt
buffer A (50 mM Tris, 500 mM NaCl, 1% Triton X-100, 1 mM DTT,
Complete protease inhibitors, pH 7.4). To Streptavidin beads in
50 lL buffer was added 10 lL gel loading dye (LDS) and the result-
ing sample was heated for 10 min at 90 C and then analysed by
SDS PAGE. To washed Streptactin beads was added 100 lL of elu-
tion buffer (10 mM biotin, 50 mM Tris, 150 mM NaCl, 1% Triton
X-100, 1 mM DTT, Complete protease inhibitors, pH 8.4); the mix-
ture incubated at 4 C for 30 min and the eluate separated from the
beads. The elution protocol was conducted a total of three times to
ensure all peptide/captured protein was released and individual
elutions were analysed by SDS PAGE.
4.8. Mass spectrometry
MALDI: Peptide samples were analysed on a Voyager DE-STR
MALDI mass spectrometer in reﬂectron or linear mode. a-cya-
nohydrocinammic acid (CHCA) matrix (1 lL, 10 mg/mL in 70% ace-
tonitrile, 30% H2O, 0.1% TFA) was spotted onto the plate and
allowed to dry. The peptide sample (1 lL) was then spotted on
top of the dried matrix and the plate dried.
LC–MS: Digested gel bands were analysed on a QSTAR Elite
(ABSciex, Foster City CA) mass spectrometer coupled online to an
Agilent 1100 series nano-LC system (Agilent Technologies, Santa
Clara CA). Samples were resuspended in buffer A (0.1% formic acid),
trapped on a Zorbax 300SB-C18 trap column (5 lm, 5  0.3 mm;
Agilent Technologies) and then separated on a Zorbax 300SB-C18
HPLC column (3.5 lm, 150 mm  75 lm; Agilent Technologies)
using a linear gradient of 5–80% buffer B (99.9% acetonitrile, 0.1%
formic acid) for 60 min at a constant ﬂow rate of 300 nL min1.
The QSTAR Elite was operated in data-dependent positive ion
mode with a selected range of 350–1850m/z. The three most
intense ions from each MS scan (charge states 2+ to 4+) were
selected for collision-induced dissociation (CID) fragmentation,
with rolling collision energy enabled and a dynamic exclusion of
30 s. Raw data were viewed and scripted to Mascot generic format
(.mgf) in Analyst 2.0 (ABSciex). Mascot generic format ﬁles were
searched against the SwissProt/Uniprot database using an in-house
Mascot server, allowing variable modiﬁcations of acetamidomethyl
(Cys) and oxidation (Met), one possible missed tryptic cleavage and
a peptide and protein tolerance of 0.2 Da for QSTAR Elite data.
4.9. Tryptic digestion of gel bands
Gel bands were excised with a scalpel and diced into 1 mm3
pieces. The gel pieces were destained with a 1:1 mixture of
25 mM NH4HCO3 and acetonitrile (3–4 treatments for 10 min
each). After destaining peptides were reduced in 50 lL of 10 mM
dithiothreitol, 100 mM NH4HCO3 at 55 C for 1 h and subsequently
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HCO3 at room temperature for 30 min in the dark. The gel plugs
were washed several times with a 1:1 mixture of 25 mM NH4HCO3
and acetonitrile and then dehydrated in 100% acetonitrile and
dried under vacuum. 20–30 lL Trypsin (sequencing grade, Pro-
mega, 12 ng/lL) was added and the gel pieces were left to rehy-
drate for 1 h at 4 C. The liquid was discarded and replaced with
50 lL 25 mM NH4HCO3 and the mixture was incubated overnight
at 37 C. The supernatant was removed and set aside. Another
50 ll NH4HCO3 was added to the gel pieces and they were soni-
cated for 15 min and pooled with original peptide solution. The
combined peptide solution was desalted (C18) prior to LC–MS/MS.
4.10. Preparation of GST–FOG1(1–45)
FOG1(1–45) was cloned into pGEX-6P and overexpressed in the
BL21(DE3) strain of E. coli using 1 mM IPTG induction at 18 C for
16 h. Cell pellets were lysed by sonication (in 50 mM Tris pH 8.0,
50 mM NaCl, 0.5 mM PMSF, 0.1% b-mercaptoethanol, 0.1 mg/mL
lysozyme, 10 lg/mL DNase I) and clariﬁed by centrifugation.
25 mL of clariﬁed solution was bound to 240 lL glutathione
Sepharose beads at 4 C for 1 h. The beads were washed several
times (50 mM Tris, 500 mM NaCl, 1% Triton X-100, 1 mM DTT,
Complete protease inhibitors, pH 7.4) and used directly in pull-
down experiments.
4.11. Dot blot analysis
An elution from a peptide-4 pulldown or a buffer control were
spotted onto activated PVDF membrane and the membrane
blocked using 4% skim milk powder in PBS-T. The membrane was
then washed three times for 5 min with PBS-T before incubation
with primary antibody overnight. The primary antibodies used
were rabbit aCHD4, mouse aHDAC1, mouse aHDAC2, rabbit
aMTA1 and rabbit aRbAp46. aCHD4 and aRbAp46 were used in
a 1:1000 dilution in PBS-T with 5% BSA and aHDAC1, aHDAC2
and aMTA1 were used in a 1:2500 dilution in PBS-T with 5% skim
milk powder. After overnight incubation membranes were washed
with PBS-T three times for 5 min before incubation with appropri-
ate secondary antibody in 1:3000 dilution in PBS-T with 5% skim
milk powder for 1 h. Membranes were again washed before being
visualized usingWestern Lightning™ Illumination kit (PerkinElmer
LAS, Inc.) with a variety of exposure times.
4.12. ATP-driven remodeling reactions
Production and puriﬁcation of recombinant Saccharomyces cere-
visiae CHD1(DC1305), nucleosome assembly and the ATP-driven
sliding assays were performed essentially as described in.25,26
Brieﬂy, nucleosomes were assembled using standard salt-gradient
dialysis methods using recombinant Xenopus laevis histones and
PCR-generated Cy3-labelled DNA fragments containing the 147 bp
601 nucleosome positioning sequence ﬂanked by 47 bp DNA on
one side. The sliding reactions contained 50 mM Tris pH 7.5,
50 mM NaCl, 3 mM MgCl2, 0.5 pmol of nucleosome, and 1 mM
ATP (where indicated). Reactions were started by the addition ofremodeling enzyme, CHD1 (3.75 pmol) or NuRD (1.5, 0.5,
0.17 lL), and were incubated at 37 C for 1 h. The reactions were
stopped by placing on ice and the addition of 500 ng sheared sal-
mon sperm DNA and sucrose to 5% w/v. Products were resolved
on a 0.25  TBE 6% native polyacrylamide gel run for 50 min at
200 V at 4 C. Gels were imaged on an FLA-9000 ﬂuorescence
scanner.
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